Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL352831 | 1.00 | DRD2 (0.49) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL3943582 | 1.00 | DRD2 (0.49) | DRD2BTKEPHX1KDM1AMAOB | |
| Hydrochloric Acid SCHEMBL3513679 | 0.98 | DRD2 (0.48) | DRD2BTKEPHX1KDM1AMAOB | |
| Hydrochloric Acid SCHEMBL30722908 | 0.98 | DRD2 (0.48) | DRD2BTKEPHX1KDM1AMAOB | |
| Hydrochloric Acid SCHEMBL3513680 | 0.98 | DRD2 (0.48) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL3900940 | 0.90 | BTK (0.54) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL5549963 | 0.90 | BTK (0.54) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL3899249 | 0.90 | BTK (0.54) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL5524221 | 0.90 | BTK (0.54) | DRD2BTKEPHX1KDM1AMAOB | |
| SCHEMBL23185506 | 0.89 | DRD2 (0.50) | DRD2BTKEPHX1KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025045761-A1 | MOLECULAR GLUE DEGRADERS AND USES THEREOF | MABLINK BIOSCIENCE (FR) | 2025-03-06 | — | — | WO | disclosed |
| WO-2025045758-A1 | ANTIBODY-DRUG CONJUGATES BASED ON MOLECULAR GLUE DEGRADERS AND USES THEREOF | MABLINK BIOSCIENCE (FR) | 2025-03-06 | — | — | WO | disclosed |
| EP-4512427-A1 | ANTIBODY-DRUG CONJUGATES BASED ON MOLECULAR GLUE DEGRADERS AND USES THEREOF | Mablink Bioscience (FR) | 2025-02-26 | — | — | EP | disclosed |
| EP-4512806-A1 | MOLECULAR GLUE DEGRADERS AND USES THEREOF | Mablink Bioscience (FR) | 2025-02-26 | — | — | EP | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2023109959-A1 | CDK9 INHIBITOR AND USE THEREOF | 药捷安康(南京)科技股份有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023016447-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-02-16 | — | — | WO | disclosed |
| CN-115315423-A | Substituted aryl compounds | 先声药业有限公司 | 2022-11-08 | — | — | CN | disclosed |
| WO-2022180150-A1 | IMIDAZO[1,2-A]PYRAZINES AS INHIBITORS OF HASPIN AND THERAPEUTIC USES THEREOF | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2022-09-01 | — | — | WO | disclosed |
| EP-1023061-A1 | SOMATOSTATIN AGONISTS | Merck & Co., Inc. (US) | 2000-08-02 | — | — | EP | disclosed |
| US-6057338-A | USEFUL IN THE TREATMENT OF DIABETES, CANCER, ACROMEGALY, RESTENOSIS, DEPRESSION, IRRITABLE BOWEL SYNDROME, PAIN AND DIABETIC RETINOPATHY | MERCK & CO., INC. (US) | 2000-05-02 | — | — | US | disclosed |
| EP-0835109-A4 | PYRIDINONE-THROMBIN INHIBITORS | MERCK & CO INC (US) | 1999-02-03 | — | — | EP | disclosed |
| WO-1998044921-A1 | SOMATOSTATIN AGONISTS | MERCK & CO., INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| US-5744486-A | Pyridinone thrombin inhibitors | MERCK & CO., INC. (US) | 1998-04-28 | — | — | US | disclosed |
| EP-0835109-A1 | PYRIDINONE-THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 1998-04-15 | — | — | EP | disclosed |
| US-5714485-A | Piperidine and hexahydropyridazine thrombin inhibitors | MERCK & CO., INC. (US) | 1998-02-03 | — | — | US | disclosed |
| US-5668289-A | Pyridinone thrombin inhibitors | MERCK & CO., INC. (US) | 1997-09-16 | — | — | US | disclosed |
| WO-1997001338-A1 | PYRIDINONE-THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1997-01-16 | — | — | WO | disclosed |
| US-5510369-A | ANTICOAGULANTS | MERCK & CO., INC. (US) | 1996-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | HSD17B13, HSD17B3, HSD17B1 | DRD2 4210/4885BTK 3182/4885EPHX1 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.